ROSEN, A LEADING LAW FIRM, Encourages Reata Pharmaceuticals, Inc. Investors to Secure Counsel Before Important February 18 Deadline in Securities Class Action - RETA
ROSEN, A LEADING LAW FIRM, Encourages Reata Pharmaceuticals, Inc. Investors to Secure Counsel Before Important February 18 Deadline in Securities Class Action
Jan 29, 2022 by PR Newswire
Key Facts
- NEW YORK, Jan. 29, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) between November 9, 2020 and December 8, 2021, inclusive (the "Class Period"), of the important February 18, 2022 lead plaintiff deadline.
- SO WHAT: If you purchased Reata Pharmaceuticals securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
- WHAT TO DO NEXT: To join the Reata Pharmaceuticals class action, go to http://www.rosenlegal.com/cases-register-2230.html or call Phillip Kim, Esq.
- The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
ORGANIZATION
GROUP
MONEY
PERSON
GEOGRAPHY
MISCELLANEOUS
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2021 Kwhen Inc.
Was this content valuable for you?